Cost-effectiveness of spironolactone in patients with severe heart failure

Tilson, Lesley; McGowan, B; Ryan, M; Barry, Michael

doi:10.1007/bf02915250

Cited by 13 publications

(21 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29, [118][119][120][121][122] None of these studies attempted to undertake a direct comparison of the cost-effectiveness of spironolactone versus eplerenone. Two of the studies reported the cost-effectiveness of spironolactone versus standard care in patients with severe chronic HF and the remainder evaluated the cost-effectiveness of eplerenone versus standard care in patients with HF after acute MI (AMI).…”

Section: Resultsmentioning

confidence: 99%

“…A useful summary of the wider set of cost-effectiveness studies for eplererone has been previously published. 33 The following sections provide a detailed critique of the cost-effectiveness evidence from the three main studies included 29,118,120 and an assessment of the quality and relevance of the data from the perspective of the UK NHS. A quality assessment checklist for each study is provided in Appendix 4.…”

Section: Resultsmentioning

confidence: 99%

“…The study by Tilson et al 120 was designed to establish the cost-effectiveness of spironolactone when added to standard therapy in patients with severe chronic HF in an Irish health-care setting. The two treatment strategies were: spironolactone in combination with standard therapy and standard therapy alone.…”

Section: Overviewmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

McKenna

Burch²,

Suekarran³

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies ...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

McKenna

Burch²,

Suekarran³

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…However, in these studies there was a drop of only 5%. This is probably caused by the studies conducted using specific diuretic that spironolactone 16 . At the cost of services and laboratory results, it was found that the group of diuretics and ACE inhibitors to pay more than the diuretic group without ACE inhibitors, but was not statistically Tabel 6.…”

Section: Discussionmentioning

confidence: 99%

Cost Analysis of Combination Diuretic Therapy with Ace-Inhibitors to Diuretic Therapy without Ace-Inhibitors in Heart Failure Patients

Pribadi

Dwiprahasto

Thobari

2016

Bangladesh J Med Sci

View full text Add to dashboard Cite

Abstract:Background: Heart failure is the final stage of the entire heart disease and become a major health problem because of the high morbidity and mortality. Diuretic combination therapy with ACE inhibitors compared to diuretic therapy without ACE inhibitors will affect the costs and hospitalization for heart failure patients; so it can be used to study Pharmacoeconomics. Method and Design: This study is an analytic observational retrospective cohort study design. Researchers compared the cost analysis between groups having diuretic combination therapy with an ACE inhibitor and diuretic therapy without ACE inhibitors. Data taken with a total sampling of heart failure databases claimed prescribing health insurance between January 1, 2010 until December 31, 2011. Results: Out of the 377 patients of the study population, 64 patients received combination therapy with ACE inhibitors and diuretics, and 60 patients received diuretic therapy without ACE inhibitors. The analysis showed that the total cost was Rp. 4.96 million and Rp. 5.14 million; the average total inpatient days a year was 10.67 days and 7.00 days. Conclusion: This study showed that the diuretic combination therapy with an ACE inhibitor is more cost-effective. Further research is needed to assess the total costs and effectiveness of therapy with more number of subjects and longer periods.

show abstract

“…The number of inpatient days was taken from Daly et al (2007: 69 (2006: 11) The unit costs were based on a study by Tilson et al (2003) GP Consultations (public health system)…”

Section: Public Psychiatric Hospitalsmentioning

confidence: 99%

The Economics of Mental Health Care in Ireland

O’Shea¹,

Kennelly²

2008

PsycEXTRA Dataset

View full text Add to dashboard Cite

Cost-effectiveness of spironolactone in patients with severe heart failure

Abstract: This economic evaluation suggests that the addition of spironolactone to standard therapy for patients with severe chronic heart failure is not only safe and effective, but is highly cost-effective in the Irish healthcare setting.

Cited by 13 publications

References 5 publications

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

Cost Analysis of Combination Diuretic Therapy with Ace-Inhibitors to Diuretic Therapy without Ace-Inhibitors in Heart Failure Patients

The Economics of Mental Health Care in Ireland

Contact Info

Product

Resources

About